Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hogy Medical Co's Debt-to-EBITDA or its related term are showing as below:
HGYMF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.14 Max: 1.84
Current: 1.84
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hogy Medical Co was 1.84. The lowest was 0.03. And the median was 0.14.
HGYMF's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.62
vs HGYMF: 1.84
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hogy Medical Co Debt-to-EBITDA Related Terms
Hogy Medical Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hogy Medical Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HGYMF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Hogy Medical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hogy Medical Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hogy Medical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hogy Medical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Hogy Medical Co (HGYMF) has a Debt-to-EBITDA of 1.42 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hogy Medical Co. This is 914% above median its historical median of 0.14. Over the past decade, Hogy Medical Co's Debt-to-EBITDA has ranged from 0.03 to 1.84.
Is Hogy Medical Co's Debt-to-EBITDA too high?
Hogy Medical Co's current Debt-to-EBITDA of 1.42 is 914% above median its 10-year median of 0.14. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.84. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. Hogy Medical Co's value of 1.42 is 12.3% below this industry median. Overall, Hogy Medical Co has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hogy Medical Co's Debt-to-EBITDA compare to ISRG and BDX?
Hogy Medical Co's Debt-to-EBITDA of 1.42 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-EBITDA is 1.62. Hogy Medical Co's value of 1.42 is 12.3% below this benchmark. Historically, Hogy Medical Co's own Debt-to-EBITDA has ranged from 0.03 to 1.84 over the past decade. While the company's 10-year median is 0.14 vs. the industry median of 1.62, Hogy Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hogy Medical Co's current Debt-to-EBITDA of 1.42 is 12.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hogy Medical Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hogy Medical Co's current Debt-to-EBITDA is 1.42, which is 914% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hogy Medical Co stock overvalued right now?
Hogy Medical Co (HGYMF) has a current Debt-to-EBITDA of 1.42. The stock's GF Value™ is $23.23, compared to a current price of $34.99 — trading 50.6% above its estimated fair value. The current Debt-to-EBITDA is 1.42, which is 914% above median its 10-year median of 0.14 and 12.3% below the Medical Devices & Instruments industry median of 1.62. Hogy Medical Co's overall GF Score™ is 57/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hogy Medical Co (HGYMF), the current Debt-to-EBITDA is 1.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hogy Medical Co (HGYMF) Overvalued in 2026?
Based on GuruFocus' analysis, Hogy Medical Co stock appears to be overvalued.
The current stock price of $34.99 is trading 50.6% above its estimated GF Value™ of $23.23.
Key valuation signals for HGYMF:
Debt-to-EBITDA: 1.42 (914% above median its 10-year median of 0.14)
GF Value™: $23.23 vs. price of $34.99 (50.6% above fair value)
Industry Position: 12.3% below the Medical Devices & Instruments median
No single metric tells the full story. See the HGYMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hogy Medical Co Ltd develops and sells products that can be used to streamline operations and improve safety at healthcare facilities. Its products are used in hospitals' operating rooms, wards, material rooms, and administrative settings. Hogy Medical receives the majority of its revenue from sales of surgical-use products. Its key products include kit products, nonwoven products, and sterilization products. The kit products contain sterilized surgical supplies for use in a specific operation. The nonwoven products include gowns, caps, equipment covers, and other accessories. Hogy's primary sterilization product is the Mekkin bag, a sterilization pouch. The vast majority of Hogy's revenue is generated in Japan.
57GF Score
Get the complete analysis for HGYMF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HGYMF has been successfully added to your 
